Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new, next-generation conjugate vaccine against typhoid has been proven at Oxford University to be safe and effective in preventing the disease, and can be used to protect both adults and children.

A study published in The Lancet is the first clinical trial to show that immunisation with a new vaccine called Vi-TT is safe, well tolerated and will have significant impact on disease incidence in typhoidendemic areas that introduce the vaccine.

The vaccine has been submitted by Bharat Biotech of India Ltd. to the World Health Organisation (WHO) for prequalification. This determines that the vaccine is safe and effective and can be procured by UNICEF for use in low-resource settings.

Typhoid is caused by the bacterium Salmonella Typhi, and is responsible for around 20 million new infections and 200,000 deaths each year, mainly in South and South East Asia and Africa.

The disease is associated with inadequate sanitation and contaminated drinking water, and common symptoms include fever, stomach pain, headache and constipation or diarrhea.

Children are especially susceptible, but the currently licensed vaccines do not confer lasting immunity in children, and/or come in inappropriate formats.

The trial was led by Professor of Paediatric Infection and Immunity at the University of Oxford, and Director of the Oxford Vaccine Group, Professor Andrew Pollard and funded by a grant from the Bill & Melinda Gates Foundation.

Read more (Department of Paediatrics website) 

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.